Press Releases 2021
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
-
Thu, 29-Jul-2021
- Posted by: Biocon Biologics
No Comments
Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19
-
Mon, 26-Jul-2021
- Posted by: Biocon Biologics
Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr;
-
Fri, 23-Jul-2021
- Posted by: Biocon Biologics
Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%
-
Thu, 29-Apr-2021
- Posted by: Biocon Biologics
Biocon Biologics’ New Monoclonal Antibodies Manufacturing Facility Wins ISPE’s 2021 Facility of the Year Honorable Mention Award
-
Wed, 28-Apr-2021
- Posted by: Biocon Biologics
Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
-
Mon, 29-Mar-2021
- Posted by: Biocon Biologics
Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets
-
Tue, 02-Mar-2021
- Posted by: Biocon Biologics
Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer
-
Mon, 01-Mar-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy®, a Biosimilar to Avastin® (Bevacizumab)
-
Mon, 01-Mar-2021
- Posted by: Biocon Biologics
Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide
-
Tue, 16-Feb-2021
- Posted by: Biocon Biologics
